

Primary Driver In The Vaxneuvance Market 2025: Impact Of High Pneumonia Prevalence On Vaccine Demand

Updated 2025 Market Reports released recently highlight trends and forecasts to 2034, offering your competitive edge today by buying early!

LONDON, GREATER LONDON, UNITED KINGDOM, February 11, 2025 /EINPresswire.com/ -- Is the Vaxneuvance Market Set to Witness Substantial Growth?



In recent years, the <u>vaxneuvance market size</u> has grown exponentially. Notably, it's projected to grow from \$XX million in 2024 to \$XX million in 2025 at a compound annual growth rate CAGR of XX%. What has boosted this growth in the historic period? It can be attributed to the rise in incidence of pneumococcal diseases, the increase in the aging population, supportive regulatory approvals, an increase in government funding for vaccination, and increase in travel and globalization.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=20428&type=smp

The growth doesn't stop there. The vaxneuvance market size is expected to see XX FCAGR in the next few years. By 2029, it will grow to \$XX million at a compound annual growth rate CAGR of XX%. The drivers of growth in the forecast period can be credited to rising chronic conditions, rising antimicrobial resistance, increasing respiratory infections in children, growing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include the development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response.

What Drives The Vaxneuvance Market Growth?

Together with the continuous innovation, the prevalence of pneumonia is expected to drive the growth of the vaxneuvance market going forward. Pneumonia, an infection causing inflammation in the air sacs of one or both lungs, leads to various symptoms such as coughing, fever, and breathing difficulties. The prevalence of pneumonia is driven by factors such as viral and bacterial infections, weakened immune systems, air pollution, and the increasing aging population, which makes individuals more susceptible to respiratory infections. Vaxneuvance comes as a knight in shining armor, protecting patients against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications.

Order Your Report Now For A Swift Delivery: <u>https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report</u>

Who Are The Key Players In The Vaxneuvance Market?

In terms of key industry players, major companies operating in the vaxneuvance market are Merck & Co. Inc., renowned for their continuous contributions to the healthcare industry. One key trend in the vaxneuvance market is the expanded indications to widen the vaccine's target patient population. This addresses unmet medical needs and enhances the vaccine's utility in preventing pneumococcal diseases across various age groups. A case in point is Merck & Co. Inc., a US-based company, which announced in June 2022 that the United States Food and Drug Administration FDA expanded vaxneuvance approval to include children aged 6 weeks to 17 years, preventing invasive pneumococcal disease caused by 15 serotypes.

How Is The Vaxneuvance Market Segmented?

The vaxneuvance market report segments:

- 1 By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media
- 2 By Distribution Channel: Pharmacies; Hospitals
- 3 By End User: Adults; Children; Geriatric Population

It's noteworthy that North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Browse for more similar reports-H1N1 Vaccine Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report</u>

Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report Cancer Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

The Business Research Company is the trusted source for global market reports. With over

15000+ reports from 27 industries covering 60+ geographies, we have built a reputation for offering comprehensive, data-rich research and insights. With 1,500,000 datasets, a blend of indepth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info

This press release can be viewed online at: https://www.einpresswire.com/article/784996210

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.